ATAI announces closing its Series D financing round, raising $157 million.
Articles
Massachusetts Community College Offers Cannabis Training Scholarships
Massachusetts’ Holyoke Community College Cannabis Education Center is offering scholarships to students who enroll in its core cannabis training program, which runs March 20 and 21.
Iowa Lawmakers Hold Historic Hearing On Psilocybin Decriminalization, But Do Not Advance Bill
In a first-of-its kind hearing, an Iowa House panel on Wednesday took up a bill to decriminalize psilocybin mushrooms in the state.
Texas Voters’ Support For Legalizing Marijuana Is Increasing, New Poll Shows
Texans’ support for legalizing marijuana has grown significantly over the past decade, according to a new poll.
MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada's First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
MINDCURE makes a CAD$500,000 strategic investment in ATMA Journey Centers, an Alberta-based psychedelics-assisted mental health clinic.
MINDCURE (CSE: MCUR | OTCQB MCURF) Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
The completed equity investment strengthens ties between MINDCURE and ATMA
Biggest Opportunities for Psychedelic Drugs OUTSIDE of Mental Health?
The Mental Health Crisis is a huge opportunity for psychedelic drugs. But the BIGGEST potential markets may exist outside of mental health.
First-of-its-kind trial finds psychedelic microdosing is equal to placebo
A first of its kind "self-blinded" trial testing the effect of psychedelic microdosing has found the anecdotally popular practice may be an example of a strong placebo effect.
Novamind Reports Company Highlights and Strong Revenue Growth in Fiscal Second Quarter
Novamind reports rising revenues and cash on hand of CAD$10 million.
What Field Trip’s Huge Financing Tells Investors
Field Trip Health just announced the 3rd largest financing by a psychedelics public company: a CAD$82.875 million bought deal. Here's what it means for investors.
Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain
Mydecine exports dried psilocybin mushrooms from Jamaica to Canada.
Field Trip Health Announces Upsize to Previously Announced Bought Deal Public Offering
With its (upsized) $82.875 million dollar financing, Field Trip establishes itself as one of the industry leaders in the psychedelics space.
Optimi Health Corp. Completes Oversubscribed $20.7 Million Initial Public Offering, and Announces Listing on the CSE
Optimi Health has commenced public trading (symbol "OPTI"). The Company raised CAD$20.7 million for its IPO financing.
Red Light Holland iMicrodose Pack Receives Authorization for the First Legal Import and Sale of Psilocybin Truffles to Brazil
TRIP gains access to the huge Brazilian market for its psilocybin truffles.
PsyBio Therapeutics Corp. Begins Trading on the TSX Venture Exchange
PsyBio has commenced trading. Its focus is on drug development for the Mental Health Crisis.